// App-Quantinova.ai

4088 : Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Robin Kate Kelley

Principal Investigators

  • Baek-Yeol Ryoo

  • Philippe Merle

  • Joong-Won Park

  • Luigi Bolondi

  • Stephen Lam Chan

  • Ho Yeong Lim

  • Ari David Baron

  • Francis Parnis

  • Jennifer Knox

  • Stephane Cattan

  • Thomas Cheung Yau

  • Julie Lougheed

  • Steven Milwee

  • Anthony El-Khoueiry

  • Ann-Lii Cheng

  • Tim Meyer

  • Ghassan K. Abou-Alfa

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • INSERM U1052, Lyon, France

  • Department of Medical and Surgical Sciences, University of Bologna and Center for Applied Biomedical Research (CRBA), S.Orsola-Malpighi Hospital, Bologna, Italy

  • Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • California Pacific Medical Center Research Institute, San Francisco, CA

  • University of Adelaide, Adelaide, Australia

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Centre Hospitalier Universitaire, Ottignies, France

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

  • Exelixis, Inc, South San Francisco, CA

  • Exelixis, Inc, South San Francisco, CA

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • The Royal Marsden Hospital, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Canada

  • Taiwan

  • Italy

  • United Kingdom

  • Australia

  • United States

  • Hong Kong

  • France

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Sorafenib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01908426

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved